Background: Guidelines are issued by most major organizations
that focus on a specific disease entity. Guidelines should be a significant
help to the practicing physician who may not be up-to-date with the recent
medical literature. Unfortunately, when conflicting guidelines for a specific
disease are published, confusion results. Purpose: This article provides a suggested guideline outcome measure that would benefit the
physician and patient. Methods: A review of 19 different guidelines for cardiovascular
disease treatment is one example of the lack of specific outcomes that currently exist. The
basic problem with most guidelines is that they do not state the expected end
result (i.e., the benefit to the
patient) if that guideline is followed. When guidelines use cardiovascular
disease risk factors to dictate therapy, the end benefit is never stated so
that the patient can make an appropriate choice of which (if any) guideline to
follow. Results: A good
example is guidelines published by the American
Heart Association for reducing cardiovascular disease. These guidelines
are risk factor based and only indicate that cardiovascular disease would be
reduced if followed. No specific percentage in the reduction of the incidence
of disease is given. In contrast, when elimination of the disease is the stated
goal of the guideline, the end result is clear. To date, this goal has been
stated by only one organization devoted to eliminating cardiovascular disease. Conclusion
References
[1]
Khanji, M.Y., Bicalho, V.V.S., van Waardhuizen, C.N., Ferket, B.S., Petersen, S.E. and Hunink, M.G.M. (2016) Cardiovascular Risk Assessment: A Systematic Review of Guidelines. Annals of Internal Medicine, 165, 713-722.
https://doi.org/10.7326/M16-1110
Giannini, J., Padilla, J., Eaton, R.P., Gonzales, K. and Schade, D.S. (2022) Prevention of Coronary Heart Disease: A Translational Clinical Challenge. World Journal of Cardiovascular Diseases, 12, 11-23. https://doi.org/10.4236/wjcd.2022.121002
[4]
Varbo, A. and Nordestgaard, B.G. (2016) Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 2133-2155.
https://doi.org/10.1161/ATVBAHA.116.308305
[5]
Joshi, P.H., Khokhar A.A., Massaro, J.M., Lirette, S.T., Griswold, M.E., Martin, S.S., Blaha, M.J., Kulkarni, K.R., Correa, A., D’AgostinoSr, R.B, Jones, S.R., Toth, P.P. and The Lipoprotein Investigators Collaborative (LIC) Study Group (2016) Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 5, e002765. https://doi.org/10.1161/JAHA.115.002765
[6]
Schade, D.S., Obenshain, S., Hickey, M., Febbo, J., Wann, S. and Eaton, R.P. (2022) Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque—Provided by the Society for the Prevention of Symptomatic Heart Disease. World Journal of Cardiovascular Diseases, 12, 320-341. https://doi.org/10.4236/wjcd.2022.126032
[7]
American Heart Association (2017) Cardiovascular Disease: A Costly Burden for America Projections Through 2035.
https://www.heart.org/-/media/Files/Get-Involved/Advocacy/Burden-Report-Consumer-Report.pdf
[8]
Schade, D.S. and Eaton, R.P. (2019) A Simplified Approach to Reducing Cardiovascular Risk. The Journal of Clinical Endocrinology & Metabolism, 104, 6033-6039.
https://doi.org/10.1210/jc.2018-02509
[9]
Hecht, H., Blaha, M.J., Berman, D.S., Nasir, K., Budoff, M., Leipsic, J., et al. (2017) Clinical Indications for Coronary Artery Calcium Scoring in Asymptomatic Patients: Expert Consensus Statement from the Society of Cardiovascular Computed Tomography. Journal of Cardiovascular Computed Tomography, 11, 157-168.
https://doi.org/10.1016/j.jcct.2017.02.010
[10]
Nabi, F., Chang, S.M., Pratt, C.M., Peterson, L.E., Frias, M.E. and Mahmarian, J.J. (2010) Coronary Artery Calcium Scoring in the Emergency Department: Identifying Which Patients with Chest Pain Can Be Safely Discharged Home. Annals of Emergency Medicine, 56, 220-229. https://doi.org/10.1016/j.annemergmed.2010.01.017
[11]
Lindholt, J.S., Sogaard, R., Rasmussen, L.M., Mejldal, A., Lambrechtsen, J., Steffensen, F.H., et al. (2022) Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. The New England Journal of Medicine, 387, 1385-1394.
https://doi.org/10.1056/NEJMoa2208681
[12]
Hecht, H.S. (2008) The Deadly Double Standard (The Saga of Screening for Subclinical Atherosclerosis). The American Journal of Cardiology, 101, 1805-1807.
https://doi.org/10.1016/j.amjcard.2008.02.086
[13]
Arnett, D.K., Blumenthal, R.S., Albert, M.A., Buroker, A.B., Goldberger, Z.D., Hahn, E.J., et al. (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140, e596-e646.
https://doi.org/10.1161/CIR.0000000000000678